Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Barchiesi, F.
Right arrow Articles by Scalise, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barchiesi, F.
Right arrow Articles by Scalise, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 65-70
© 1999 The British Society for Antimicrobial Chemotherapy

In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans

Francesco Barchiesi*, Domenico Gallo, Francesca Caselli, Luigi Falconi Di Francesco, Daniela Arzeni, Andrea Giacometti and Giorgio Scalise

Istituto di Malattie Infettive e Medicina Pubblica Università degli Studi di Ancona, Ospedale Umberto I°, Largo Cappelli 1, 60121, Ancona, Italy

Treatment failures can occur in AIDS patients infected with Cryptococcus neoformans,despite aggressive antifungal therapy. Combination regimens with additive or synergic drugs could provide additional options for treating cryptococcosis. We studied the effects of itraconazole combined with flucytosine against 16 strains of C. neoformansvar. neoformans. Combination therapy revealed different results for the various strains, including synergy (fractional inhibitory concentration (FIC) index 0.5, 63% of the interactions), addition (FIC >0.5 to 1.0, 31% of the interactions) and indifference (FIC >1.0 to <2.0, 6% of the interactions). Antagonism (FIC >2.0) was not observed. The efficacy of combination therapy was confirmed by quantitative cfu and killing curve assays. In particular, killing curves conducted in replicating cells showed that the addition of itraconazole prevented the development of flucytosine-resistant mutants of C. neoformans. These data show that the combination of itraconazole and flucytosine is significantly more active than either drug alone against C. neoformans in vitro.

* Corresponding author. Tel: +39-71-5963467; Fax: +39-71-5963468; E-mail: cmalinf{at}popcsi.unian.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
C. Serena, B. Fernandez-Torres, F. J. Pastor, L. Trilles, M. d. S. Lazera, N. Nolard, and J. Guarro
In Vitro Interactions of Micafungin with Other Antifungal Drugs against Clinical Isolates of Four Species of Cryptococcus
Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2994 - 2996.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
P. K. Mukherjee, D. J. Sheehan, C. A. Hitchcock, and M. A. Ghannoum
Combination Treatment of Invasive Fungal Infections
Clin. Microbiol. Rev., January 1, 2005; 18(1): 163 - 194.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Cuenca-Estrella
Combinations of antifungal agents in therapy-what value are they?
J. Antimicrob. Chemother., November 1, 2004; 54(5): 854 - 869.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. Barchiesi, E. Spreghini, M. Maracci, A. W. Fothergill, I. Baldassarri, M. G. Rinaldi, and G. Scalise
In Vitro Activities of Voriconazole in Combination with Three Other Antifungal Agents against Candida glabrata
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3317 - 3322.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. D. Johnson, C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex
Combination Antifungal Therapy
Antimicrob. Agents Chemother., March 1, 2004; 48(3): 693 - 715.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Schwarz, F. Dromer, O. Lortholary, and E. Dannaoui
In Vitro Interaction of Flucytosine with Conventional and New Antifungals against Cryptococcus neoformans Clinical Isolates
Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3361 - 3364.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. Barchiesi, A. M. Schimizzi, F. Caselli, A. Novelli, S. Fallani, D. Giannini, D. Arzeni, S. Di Cesare, L. F. Di Francesco, M. Fortuna, et al.
Interactions between Triazoles and Amphotericin B against Cryptococcus neoformans
Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2435 - 2441.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.